FMP
Eiger BioPharmaceuticals, Inc.
EIGR
NASDAQ
Inactive Equity
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
1.73 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Dr. David Apelian M.B.A., M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.eigerbio.comexchange
NASDAQ
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clini...
CIK
0001305253
ISIN
US28249U2042
CUSIP
28249U105
Address
2155 Park Boulevard
Phone
650 272 6138
Country
US
Employee
56
IPO Date
Jan 30, 2014
Financial Statement
Earnings
EIGR Financial Summary
CIK
0001305253
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
28249U105
ISIN
US28249U2042
Country
US
Price
1.73
Beta
1.84
Volume Avg.
120.79k
Market Cap
2.55M
Shares
-
52-Week
1.1-43.35
DCF
-0.36
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.eigerbio.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EIGR News
Market Watch
Apr 1, 2024
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
InvestorPlace
Sep 13, 2023
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. According to a press release from the company, it has discontinued its Phase 3 LIMT-2 study.
Seeking Alpha
Jun 16, 2023
Eiger BioPharmaceuticals: Wall Street Has High Expectations ...
Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way.
Pulse2
Feb 9, 2023
EIGR Stock: 23.53% Surge Explanation
The stock price of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) surged by 23.53% today. This is why.
Barrons
Jan 18, 2023
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
PennyStocks
Dec 29, 2022
Best Penny Stocks To Buy? 4 To Watch Before 2023
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?
PennyStocks
Dec 28, 2022
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
PRNewsWire
Dec 7, 2022
Eiger BioPharmaceuticals to Host Conference Call to Discuss ...
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.
